STAG2 is a Clinically Relevant Tumor Suppressor in Pancreatic Ductal Adenocarcinoma

doi:10.1201/b17138-14

Cited by 6 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it significantly inhibits the growth of BGC-823 and CD44 + cells in a dose-dependent manner, suppressing the proliferation of spheroid cell colonies and inhibiting their clone-forming capacity. In vivo, ACBP-3 alone or in combination with cisplatin suppresses xenograft tumor growth, and this peptide enhances the chemotherapy tolerance of mice by reducing the toxicity of the treatment during long-term experiments (15,16). The Su group also investigated the anticancer activity of ACBPs in a human colorectal tumor cell line (HCT116) in vitro and in vivo (17).…”

Section: Animal Sources Of Bioactive Peptides With Anticancer Activitymentioning

confidence: 99%

Anticancer potential of bioactive peptides from animal sources

et al. 2017

View full text Add to dashboard Cite

Cancer is the most common cause of human death worldwide. Conventional anticancer therapies, including chemotherapy and radiation, are associated with severe side effects and toxicities as well as low specificity. Peptides are rapidly being developed as potential anticancer agents that specifically target cancer cells and are less toxic to normal tissues, thus making them a better alternative for the prevention and management of cancer. Recent research has focused on anticancer peptides from natural animal sources, such as terrestrial mammals, marine animals, amphibians, and animal venoms. However, the mode of action by which bioactive peptides inhibit the proliferation of cancer cells remains unclear. In this review, we present the animal sources from which bioactive peptides with anticancer activity are derived and discuss multiple proposed mechanisms by which these peptides exert cytotoxic effects against cancer cells.

show abstract

Section: Animal Sources Of Bioactive Peptides With Anticancer Activitymentioning

confidence: 99%

Anticancer potential of bioactive peptides from animal sources

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Our previous study found that ACBPs had a remarkable ability to inhibit human gastric cancer growth both in vitro and in vivo [11] . In addition, ACBPs were found to sensitize tumor cells to cisplatin [12] . However, the mechanisms responsible for the anticancer activity of the ACBPs remain undiscovered.…”

Section: Discussionmentioning

confidence: 99%

Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway

Shi

Yan

et al. 2015

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…In culture, ACBPs were found to inhibit tumor growth in nude mice bearing Dutch gallbladder carcinoma GBS-SD, Dutch GC BGS-823, and GC MGS-803 cells via a sustained medication mode every few days (15,16). Previously, we demonstrated that ACBP combined with lower cisplatin doses could achieve antitumor efficacy similar to the efficacy of higher doses of cisplatin alone via a sustained medication mode (17). However, the potential antitumor efficacy of short-term intermittent ACBP (induced or normal) medication modes and the combination with chemotherapeutics has not been previously demonstrated.…”

Section: New Bioactive Peptide Reduces the Toxicity Of Chemotherapy Dmentioning

confidence: 99%

“…All treatments were administered on day 3, 7, 10, 14. The dose of L-OHP (10 mg/kg) was chosen by our experiment screening from 1 to 30 µg/ml, which was chosen based on a similar previous study from 75 to 130 mg/m 2 (6,13), while the dose of ACBP was chosen based on our own previous study (17). The tumor volume (V) was measured every 3 days by a vernier caliper after the tumors formed.…”

Section: Dose-dependent Expression Of Cytochrome C and Caspase-9 In Mmentioning

confidence: 99%

New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity

Ouyang

et al. 2017

Oncology Reports

View full text Add to dashboard Cite

Anticancer bioactive peptide (ACBP) is extracted from normal goat spleens and exhibits antitumor activity alone and in combination with low cisplatin doses to achieve antitumor efficacy similar to higher cisplatin doses via sustained medication modes. In the present study, we investigated whether elevated levels of induced or normal ACBP in MKN‑45 gastric cancer (GC) cells may reduce their toxicity to oxaliplatin (L‑OHP) in a dose‑dependent manner. The growth inhibition rate (IR), morphological changes and gene expression were examined in MKN‑45 GC cells. Compared with normal ACBP, induced ACBP alone significantly enhanced the anticancer activity of L‑OHP‑mediated apoptosis and reduced the amount and side‑effects of L‑OHP (P<0.05). The inhibition of cancer cell growth at high concentrations of induced ACBP and L‑OHP was significantly more effective than at low concentrations. In addition, for the first time, we examined the potential of a combination of induced ACBP and L‑OHP to increase L‑OHP sensitivity in human gastric carcinoma xenograft tumors. Nude mice were implanted with human gastric carcinoma MKN‑45 cells and treated with an intraperitoneal injection of 0.5 ml of normal saline, 30 µg/ml ACBP, 20 µg/ml L‑OHP or 30 µg/ml ACBP + 20 µg/ml L‑OHP [combination of anticancer bioactive peptide and oxaliplatin (A+L)] via the tail vein twice a week. In vivo short‑term intermittent use of induced ACBP alone significantly inhibited MKN‑45 tumor growth. The combination of induced ACBP and L‑OHP also significantly improved the quality of life of the nude mice and reduced the toxicity of L‑OHP. Based on flow cytometry and gene expression analyses, A+L significantly increased the proportion of cells in the G2/M phase (P<0.05) relative to ACBP or L‑OHP alone, and short‑term intraperitoneal injection of ACBP increased the sensitizing effect of L‑OHP. Collectively, these results suggest that high levels of induced ACBP in combination with L‑OHP via a short‑term intermittent medication mode could be a useful clinical therapeutic strategy for GC.

show abstract

STAG2 is a Clinically Relevant Tumor Suppressor in Pancreatic Ductal Adenocarcinoma

Cited by 6 publications

References 2 publications

Anticancer potential of bioactive peptides from animal sources

Anticancer potential of bioactive peptides from animal sources

Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway

New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity

Contact Info

Product

Resources

About